Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$3.53
+3.7%
$3.07
$2.18
$7.90
$37.93M0.7523,445 shs7,654 shs
CareDx, Inc. stock logo
CDNA
CareDx
$18.45
-4.1%
$17.78
$14.09
$34.84
$1.03B2.19919,417 shs716,370 shs
Elekta AB stock logo
EKTAY
Elekta
$4.98
-4.0%
$5.12
$4.36
$7.13
$1.91B1.215,495 shs2,500 shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
$0.02
$80K1.5923.72 million shs75 shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$26.34
-4.3%
$28.10
$19.73
$47.32
$2.06B2.07917,765 shs691,394 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00%+10.29%+16.38%-10.60%-44.67%
CareDx, Inc. stock logo
CDNA
CareDx
0.00%-0.18%-1.66%+8.32%+23.60%
Elekta AB stock logo
EKTAY
Elekta
0.00%+2.98%+0.78%+14.32%-20.79%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%-57.14%
Veracyte, Inc. stock logo
VCYT
Veracyte
0.00%+0.47%+0.18%-6.84%+27.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
CareDx, Inc. stock logo
CDNA
CareDx
4.4372 of 5 stars
3.32.00.04.23.50.81.9
Elekta AB stock logo
EKTAY
Elekta
3.2839 of 5 stars
0.05.01.70.02.31.71.9
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
3.7633 of 5 stars
3.41.00.04.33.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00
N/AN/AN/A
CareDx, Inc. stock logo
CDNA
CareDx
2.67
Moderate Buy$30.3364.41% Upside
Elekta AB stock logo
EKTAY
Elekta
2.00
HoldN/AN/A
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
2.70
Moderate Buy$40.9055.28% Upside

Current Analyst Ratings Breakdown

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Elekta AB stock logo
EKTAY
Elekta
Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $42.00
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $41.00
5/5/2025
CareDx, Inc. stock logo
CDNA
CareDx
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.00
5/5/2025
CareDx, Inc. stock logo
CDNA
CareDx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
4/17/2025
CareDx, Inc. stock logo
CDNA
CareDx
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$34.00 ➝ $26.00
4/9/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$45.00 ➝ $37.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$70.67M0.54N/AN/A$7.39 per share0.48
CareDx, Inc. stock logo
CDNA
CareDx
$333.79M3.08$1.30 per share14.15$7.06 per share2.61
Elekta AB stock logo
EKTAY
Elekta
$1.71B1.12$0.59 per share8.48$2.19 per share2.27
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
Veracyte, Inc. stock logo
VCYT
Veracyte
$445.76M4.63$0.99 per share26.53$15.17 per share1.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$47.49M-$1.89N/AN/A-45.41%-38.33%-25.34%N/A
CareDx, Inc. stock logo
CDNA
CareDx
$52.55M$1.1516.04N/AN/A19.79%21.16%14.25%7/30/2025 (Estimated)
Elekta AB stock logo
EKTAY
Elekta
$22.37M$0.0599.6211.58N/A1.15%11.55%3.75%8/27/2025 (Estimated)
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
$24.14M$0.4164.2536.58N/A7.13%6.14%5.60%8/5/2025 (Estimated)

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
CareDx, Inc. stock logo
CDNA
CareDx
$0.12N/AN/AN/A$90.72 millionN/A
6/6/2025Q1 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.17N/A-$0.17N/A$18.34 million
5/28/2025Q4 2025
Elekta AB stock logo
EKTAY
Elekta
$0.13$0.11-$0.02-$0.10$507.19 million$503.22 million
4/30/2025Q1 2025
CareDx, Inc. stock logo
CDNA
CareDx
$0.06$0.09+$0.03-$0.19$84.56 million$84.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Elekta AB stock logo
EKTAY
Elekta
$0.122.41%N/A240.00%N/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A
3.02
2.76
CareDx, Inc. stock logo
CDNA
CareDx
N/A
4.11
3.84
Elekta AB stock logo
EKTAY
Elekta
0.70
1.09
0.86
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
5.10
4.78

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
CareDx, Inc. stock logo
CDNA
CareDx
N/A
Elekta AB stock logo
EKTAY
Elekta
N/A
Invitae Co. stock logo
NVTA
Invitae
61.28%
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
CareDx, Inc. stock logo
CDNA
CareDx
4.40%
Elekta AB stock logo
EKTAY
Elekta
41.28%
Invitae Co. stock logo
NVTA
Invitae
0.74%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1,39010.76 million7.50 millionNot Optionable
CareDx, Inc. stock logo
CDNA
CareDx
74055.68 million53.23 millionOptionable
Elekta AB stock logo
EKTAY
Elekta
4,718383.57 million225.23 millionNot Optionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79078.32 million77.22 millionOptionable

Recent News About These Companies

Veracyte, Inc. (VCYT) - Yahoo Finance
Veracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"

New MarketBeat Followers Over Time

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$3.52 +0.13 (+3.68%)
As of 03:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

CareDx stock logo

CareDx NASDAQ:CDNA

$18.45 -0.79 (-4.11%)
As of 04:00 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Elekta stock logo

Elekta OTCMKTS:EKTAY

$4.98 -0.21 (-4.05%)
As of 03:58 PM Eastern

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$26.34 -1.17 (-4.25%)
Closing price 04:00 PM Eastern
Extended Trading
$26.46 +0.12 (+0.46%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.